Radiofrequency Ablation Versus Hemithyroidectomy for Small Thyroid Cancers
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a multicenter randomized controlled trial including patients with small (\<2 cm) suspected or confirmed thyroid cancers. Patients are included after informed consent and randomized to one of two treatments. One treatment is a standard henithyroidectomy and the second treatment is radiofrequency ablation (RFA) of the specific tumor. The investigators will evaluate initial outcome of the allocated treatment, thyroid hormonal function, oncologic safety, quality of life, and treatment costs in a follow-up period of five years after treatment. The overall aim of the study is to improve patient's health by reducing the number of operations on small thyroid cancers. In patients with these small tumors, the long-term adverse outcome may be higher than possible benefits from the operation. For participants undergoing surgical treatment with HT, the investigators will measure final histology and both beneficial and adverse outcome from the operation. For participants undergoing RFA, the investigators expect to reduce the need for thyroid hormonal substitutions, reduce the surgical adverse outcomes, reduce treatment costs and increase QoL without a reduction in oncologic safety and outcome.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Jeden guz w tarczycy potwierdzony lub podejrzewany jako rak
- •Rozmiar guza mniejszy niż 2 cm we wszystkich wymiarach
- •Zgoda pacjenta na udział w badaniu
✗ Disqualifies
- •Przerzuty nowotworu do węzłów chłonnych
- •Podejrzenie rozprzestrzeniania się raka poza tarczycę
- •Poprzednia operacja tarczycy
- •Zaburzenia wapnia i parathormonu
- •Ciąża
- •Brak możliwości wyrażenia świadomej zgody
Simplified criteria — AI translation
Trial details
- Minimum age
- 30 Years
- Last updated (source)
- September 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Department of Otorhinolaryngology, Aarhus University Hospital
Aarhus, Denmark
Trial contact
Sofie Louise Rygaard, MD, PhD
Lars Rolighed, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.